Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for Gamma Glutamyl Transferase (GGT) testing, effective May 15, 2026. Here's what billing teams need to do.
CMS updated its Gamma Glutamyl Transferase coverage policy — a change that affects labs, hospital outpatient departments, and any practice billing GGT testing to Medicare. The policy document does not list specific CPT or HCPCS codes in the version reviewed here. Even so, this modification signals a shift in how CMS approaches medical necessity and reimbursement for this liver enzyme test. If your team bills GGT testing regularly, audit your documentation practices before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Gamma Glutamyl Transferase |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium |
| Specialties Affected | Clinical laboratories, gastroenterology, hepatology, internal medicine, hospital outpatient departments |
| Key Action | Review GGT test documentation for medical necessity and update billing workflows before May 15, 2026 |
CMS Gamma Glutamyl Transferase Coverage Criteria and Medical Necessity Requirements 2026
GGT is a liver enzyme test used to evaluate liver disease, bile duct obstruction, and alcohol-related liver damage. For Medicare billing purposes, GGT testing must meet CMS medical necessity standards — meaning there must be a documented clinical reason tied to a covered diagnosis.
The coverage policy for GGT under the Centers for Medicare & Medicaid Services has been modified as of May 15, 2026. The specific criteria in the updated version of this policy are not fully published in the reviewed document. That gap matters — if your practice bills GGT routinely as part of a hepatic panel or standalone order, you need to know whether CMS has tightened or loosened the indications.
GGT is often ordered alongside other liver function tests. CMS coverage policy for combination testing can trigger claim denial if the medical record doesn't clearly document why GGT was ordered separately, or why it was clinically necessary beyond a standard metabolic panel. Your documentation should name the clinical question GGT answers — not just the diagnosis.
Medical necessity documentation for GGT billing generally hinges on a few clinical scenarios: suspected hepatobiliary disease, monitoring of known liver conditions, evaluation of elevated alkaline phosphatase to rule out bone origin, and alcohol use disorder monitoring. CMS expects your ordering provider's notes to reflect that clinical reasoning explicitly.
Prior authorization is not commonly required for routine lab tests under traditional Medicare fee-for-service. However, Medicare Advantage plans operated by Cigna Healthcare, UnitedHealthcare, and others may apply their own prior authorization rules. If your patient population skews toward Medicare Advantage, verify prior auth requirements with each plan before billing GGT.
CMS Gamma Glutamyl Transferase Coverage Criteria at a Glance
The policy document reviewed here does not provide a complete indication-level breakdown. The table below reflects established CMS and Medicare Administrative Contractor guidance for GGT testing, which frames how medical necessity is typically evaluated for this test. Confirm these against the updated May 15, 2026 policy language once CMS publishes the full document.
| Indication | Status | Notes |
|---|---|---|
| Suspected hepatobiliary disease | Covered (when documented) | Clinical documentation must support the indication |
| Elevated alkaline phosphatase — differentiating liver vs. bone origin | Covered (when documented) | GGT is specifically useful here; document the diagnostic question |
| Monitoring known chronic liver disease | Covered (when documented) | Frequency matters — excess frequency without documented rationale risks denial |
| Alcohol use disorder monitoring | Covered (when documented) | Connect the test order to the monitoring plan in the clinical note |
| Routine screening without symptoms or diagnosis | Not Covered | CMS does not cover GGT as a general wellness screen under Medicare |
| Repeated testing without change in clinical status | Risk of Denial | Lack of documented clinical change is a common audit trigger |
CMS Gamma Glutamyl Transferase Billing Guidelines and Action Items 2026
This is where the rubber meets the road. The modification effective May 15, 2026 is a signal — CMS doesn't update a coverage policy without a reason. Until the full policy text is published, treat this as a prompt to tighten your GGT billing documentation now.
| # | Action Item |
|---|---|
| 1 | Pull your GGT claim volume before May 15, 2026. Run a report on all GGT claims billed to Medicare in the past 12 months. Flag any with high test frequency, missing ICD-10 codes, or diagnoses that don't clearly support liver or biliary disease. That's your audit target list. |
| 2 | Review ordering provider documentation today. GGT billing fails medical necessity review when the order reason isn't in the note. Check that your providers document the specific clinical question GGT is answering — not just the diagnosis code. "Rule out hepatic source of elevated ALP" is better than "liver disease." |
| 3 | Check your MAC's local coverage determination for GGT. CMS sets national policy, but your Medicare Administrative Contractor may have an LCD that adds or restricts indications. Search your MAC's website using the test name or the applicable CPT code. If your MAC has an active LCD for GGT or hepatic function panels, cross-reference it against this policy update. |
| 4 | Confirm prior authorization rules with Medicare Advantage plans in your payer mix. Traditional Medicare fee-for-service generally does not require prior auth for lab tests. Medicare Advantage plans do their own thing. If you have a high MA volume, call the plans or check their portals before May 15, 2026. |
| 5 | Update your billing guidelines documentation internally. If your practice or lab has internal billing guidelines for hepatic lab tests, update them to reflect the May 15, 2026 effective date. Train your billing team on what changes — even if that means waiting for the full CMS policy text and doing a rapid-cycle update. |
| 6 | Monitor CMS for full publication of the policy text. This modification is documented but the complete updated criteria are not yet in the reviewed version. Assign someone on your team to check the CMS coverage database and PayerPolicy for the full text before May 15, 2026. Don't wait until the effective date to read it. |
If your practice bills significant GGT volume to Medicare — especially in gastroenterology, hepatology, or clinical lab settings — loop in your compliance officer before May 15, 2026. A coverage policy modification on a high-volume lab test can have real revenue cycle exposure if your documentation workflows don't match the new criteria.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Gamma Glutamyl Transferase Under This Policy
The policy document reviewed for this update does not list specific CPT, HCPCS, or ICD-10 codes. CMS did not publish code-level data in the version available at the time of writing.
That's a gap worth noting. Most CMS coverage policies include the applicable CPT codes explicitly — their absence here suggests either the full policy text isn't yet published, or this modification focuses on criteria language rather than code additions or deletions.
What Billing Teams Should Know About GGT Codes
The CPT code most commonly associated with Gamma Glutamyl Transferase testing is a single analyte lab code in the chemistry section of the CPT manual. CMS assigns reimbursement for this test through the Clinical Laboratory Fee Schedule. Do not use this post as your authoritative source for the specific code — confirm the exact CPT code against the full published policy text and your MAC's current fee schedule before billing.
For ICD-10 diagnosis codes, GGT testing is typically linked to conditions in the K70–K77 range (liver diseases), K80–K87 range (gallbladder and biliary tract disorders), Z87.39 (personal history of other endocrine, nutritional, and metabolic diseases), and F10-range codes for alcohol use disorders. Again — confirm against the published policy text. Do not bill diagnosis codes that aren't supported by the medical record.
The policy does not list specific codes, so no code tables are included here. Once CMS publishes the full updated policy text, PayerPolicy will update this post with the exact code data.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.